Research on new and better ways to treat cancer. Covers radiotherapy, targeted microdroplets, nerve-injury protection, drug combinations, and tumor models.
Continuous Medicaid enrollment is associated with a lower rate of late-stage lymphoma diagnosis, but fewer than half of patients are continuously enrolled before diagnosis. The study found that continuous coverage was strongly linked to a lower likelihood of late-stage diagnosis, especially in young adults.
A recent study found that only half of young cancer patients report discussing fertility preservation options with their healthcare provider. The study, which included 473 patients between the ages of 18 and 49, highlights the need for comprehensive reproductive health care in oncology treatment. Fertility preservation discussions were...
Researchers at UC Riverside develop a novel method to degrade the Pin1 protein, which is involved in pancreatic cancer development. The 'molecular crowbar' strategy has the potential to target and break down harmful proteins, offering new hope for cancer therapy.
AI models trained on limited data may misdiagnose certain populations, particularly those in underserved communities. Researchers propose six key strategies to develop fair AI models, including using diverse datasets and transparent decision-making processes.
A recent study has uncovered a genetic variant in the PSA gene that is associated with aggressive prostate cancer. This finding could lead to the development of a novel point-of-care device that can identify high-risk patients with low blood PSA levels, enabling early detection and treatment.
Researchers developed a new imaging technique using fluorescence-guided surgery to enhance visibility of tumors and nerves during head and neck cancer surgery. The technique uses two near-infrared fluorophores, one for tumors and another for facial nerves, allowing for clear differentiation between cancerous tissues and nerves.
Clinicians should avoid using 'never words' that can scare, offend, or diminish agency in patients and families dealing with serious illness. Researchers recommend alternative language and methods for clinicians to identify their own never words.
The National Comprehensive Cancer Network has updated its guidelines for genetic/familial high-risk assessment, incorporating the latest scientific research and expert recommendations to enhance screening practices and treatment options. The expanded guidelines cover various cancer types and provide guidance on genetic testing, heredit...
A joint research team at Korea University College of Medicine announced the world's first comparative results of single-port robotic thymectomy, showing a lower conversion rate to multi-port surgery and shorter hospital stays. The study demonstrated that single-port robotic thymectomy is a safer alternative to traditional VATS thymectomy.
Researchers analyzed tumor samples from 64 SCLC patients, identifying promising results for biomarkers DLL3 and TTF-1. These biomarkers showed potential as targets for therapies like Tarlatamab and improved survival rates in patients with TTF-1-positive tumors.
Scientists at Johns Hopkins Medicine identified 16 genes that breast cancer cells use to survive in the bloodstream, including MUC1, which is already in clinical trials. The research showed that hypoxic cells are able to migrate to higher oxygen levels and form metastasis in the body, leading to a worse prognosis.
A new study has found that Canadian women who did not identify as White have an earlier peak age of breast cancer diagnosis and higher proportions of cases diagnosed under age 50. They also experience an earlier peak age of death, with a 7-year gap in mortality rates compared to their White counterparts.
International oncology experts have gathered in Accra, Ghana to update cancer treatment recommendations for Sub-Saharan Africa. The NCCN Harmonized Guidelines provide context-appropriate, evidence-based care strategies tailored to the region's unique challenges.
The National Comprehensive Cancer Network has joined forces with the Vietnam National Cancer Hospital to create Harmonized Guidelines for Vietnam, a framework for improving and standardizing cancer care in the country. The guidelines are based on NCCN's Clinical Practice Guidelines in Oncology, with modifications to reflect local needs.
This prospective cohort study found that evidence-based smoking cessation treatment within 6 months of a cancer diagnosis significantly improves survival outcomes. Smoking cessation is an essential early clinical intervention for patients with cancer, supporting the maximization of survival benefits.
The University of Chicago Medical Center will build a state-of-the-art cancer pavilion with a $75 million donation from the AbbVie Foundation. The facility aims to address health inequities in cancer outcomes and provide access to cutting-edge treatments, as part of UChicago Medicine's efforts to advance global cancer care.
A pilot study by NCCN Cancer Center demonstrates the usability of HERC in advancing equitable cancer care delivery, with all participating sites strongly agreeing on its applicability. The tool features 19 practice evaluation and change recommendations to address disparity and bias in care delivery.
Researchers developed HPV16 peptide microspheres to induce specific cytotoxic T lymphocytes, leading to tumor regression in cervical cancer models. The approach combines peptide-based vaccinations with microsphere technology to enhance immune responses and eliminate tumor cells.
A new study found that CAR-T cell therapy success is predicted by three key features: the CD4/CD8 ratio in infusion products, the presence of T-cell exhaustion signals before infusion, and the expansion of T-cells during therapy. These factors can help improve treatment outcomes.
Non-Hispanic Black patients are more likely to receive inadequate care and experience poor survival outcomes due to delays in treatment initiation. Guideline-concordant care is crucial in improving survival rates among these patients.
A new discovery by Cold Spring Harbor Laboratory's Lloyd Trotman suggests that menadione, a precursor to vitamin K, can slow prostate cancer progression in mice. The supplement depletes a lipid called PI(3)P, killing cancer cells and slowing disease progression significantly.
Researchers discovered a gene-mutation pathway that can lead to targeted therapies for blood cancers. The TET2 gene's enzymatic activity regulates chromatin state and leukaemogenesis, providing new therapeutic targets.
The UCLA Urology department has been awarded $6 million to continue the IMPACT program, providing comprehensive prostate cancer treatment for underinsured and uninsured Californians. The program has helped over 2,300 men receive treatment services since its inception.
Researchers from UT Arlington sequenced RNA genes of pythons, discovering conserved pathways in humans that are activated uniquely by these snakes. This knowledge helps explain intestinal regeneration and metabolism changes, offering potential therapeutic targets.
Polyploidy, a state with extra genetic material, allows cancer cells to survive longer under DNA damage. This phenomenon explains why some cancers are resistant to anti-cancer drug treatments.
Researchers at Penn State College of Medicine have re-engineered natural killer immune cells with blue light-activated protein function, allowing them to infiltrate and kill solid tumor spheroids. The technology has shown promising results in killing breast cancer and melanoma cells within seven days.
Researchers at Osaka University demonstrated that ultra-short, high-dose proton irradiation increases cell survival rates even under normoxic conditions. This breakthrough could lead to the development of a cancer treatment method with fewer side effects.
A study analyzing Reddit posts reveals that breast cancer patients struggle with unmet emotional and financial concerns during treatment and long after. The research highlights the importance of providing adequate support and education to address these concerns.
Researchers found that ApoE protects melanoma cells from ferroptosis by increasing antioxidant capacity and neutralizing lipids. This discovery highlights the APOE gene as a critical factor in melanoma cell survival, potentially opening new avenues for treatment.
Researchers developed an AI model that uses machine learning and combination theory to predict suspicious skin lesions. The new C4C Risk Score has an accuracy of 69% and significantly outperformed existing methods, including 7PCL and Williams score.
A groundbreaking study has demonstrated the clinical success of a new nanoparticle-based, laser-guided therapy for prostate cancer treatment. The therapy successfully eliminated cancerous cells in 73% of patients after 12 months while preserving key functions and side effects.
Researchers at Japan Advanced Institute of Science and Technology have developed a novel method to culture antitumor bacteria using porous scaffolds, enhancing their anticancer properties and improving safety in animal testing. The approach resulted in improved survival rates in mice with breast cancer, including drug-resistant cases.
Researchers from IOCB Prague have created new-generation prodrug activators that can enhance the effectiveness of anti-cancer therapies by targeting malignant tumours more precisely. These compounds allow for faster release of drugs in the body, increasing the utilization of administered doses.
Researchers at ChristianaCare Gene Editing Institute use CRISPR tools to safely disable gene mutation linked to treatment-resistant melanoma. The approach targets melanoma tumor cells while leaving healthy cells alone, restoring sensitivity to anticancer drugs.
Researchers have identified a critical genetic group that is near incurable using current therapies, leading to improved survival and quality of life for children with Group 3 medulloblastoma. The study also uncovered a potential targetable mechanism for new therapies aimed at improving outcomes.
A new study found that 5-fluorouracil kills cells by interfering with RNA synthesis, not DNA damage. The findings suggest that combining 5-FU with drugs affecting RNA synthesis could make it more effective in patients with gastrointestinal cancers.
Researchers have discovered a novel immunotherapy approach using natural killer T cells to combat solid tumors. By targeting tumor-associated macrophages and promoting systemic immune responses, CAR-natural killer T cells demonstrate superior antitumor activity compared to traditional CAR-T therapy.
Researchers at Michigan Medicine have discovered a new subtype of aggressive prostate cancer and identified a potential degrader to target it. The study found that a genetic alteration in the CDK12 gene drives cancer development, and a degrader targeting this gene shows promise in destroying cancer cells.
A recent study published in Liver Cancer found that patients with diabetes mellitus and comorbid obesity are at a higher risk of liver cancer recurrence after resection. The risk is significantly higher for those with comorbid obesity, increasing by approximately 3.8 times over five years postoperatively.
Adult childhood cancer survivors experience elevated fear of cancer recurrence, emphasizing the importance of routine screening and timely symptom intervention. The study's findings suggest that fear of cancer recurrence should be a significant concern in survivorship care.
Researchers review UBA1 loss of function in VEXAS Syndrome, a hematoinflammatory disorder characterized by severe inflammation, cytopenias, and oncogenicity. They explore therapeutic options, including clone-targeting drugs, to combat this challenging disease.
Researchers discovered TERT gene activation as a key factor in determining the clinical course of pulmonary carcinoid tumours, with aggressive growth linked to telomerase activation. The study aims to improve treatment planning and targeted therapeutic strategies for cancer types.
Researchers explore immune activation and tumor-promoting transcription factor FOXM1's role in CDK4/6-MEK resistance. They suggest targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 as future treatment options for MPNST patients.
The American College of Chest Physicians has released a new clinical guideline on endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) specimen processing and handling to standardize the process. The guidelines aim to improve diagnostic yield and specimen preservation for downstream ancillary testing.
A new study found that the IOTA ADNEX ultrasound model can detect up to 96% of ovarian cancers in postmenopausal women, outperforming the current standard test. The research team recommends replacing the risk of malignancy (RMI1) test with the IOTA ADNEX model.
Scientists at Sanford Burnham Prebys have developed a clearer picture of how crucial machinery in the human cell's recycling process for obsolete and misshapen proteins—known as proteasomes—are formed. The research team shed new light on how two protein chaperones bind on the top of the alpha subunit ring as it is constructed.
Scientists at Anglia Ruskin University are collaborating with Medannex to accelerate treatment for bone cancer in children, focusing on paediatric osteosarcoma. The first-in-class therapy MDX-124 has shown promising results in preclinical tests and is being evaluated in a clinical study.
According to the Global Cancer Observatory (GLOBOCAN), lung cancer is the most common type of cancer, with 2.2 million new cases and 1.8 million deaths worldwide in 2020. China had the highest number of new cases, and incidence and mortality rates have been steadily rising from 1990 to 2019.
Researchers have developed an AI technology that can analyze mammary tissue biopsies to identify signs of damaged cells, a key indicator of breast cancer risk. The study found the AI was far better at predicting risk than current clinical benchmarks, offering improved treatment options for women.
Dr. Roger Lo has been awarded a $2 million NIH grant to investigate ways to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors. The team aims to target genetic instability and immune evasion to stabilize the melanoma genome and make it more vulnerable to immune attacks.
The #HOPE4LIVER trial demonstrated the safety and efficacy of histotripsy as a treatment for primary and metastatic liver tumors, achieving a 95% technical success rate. The procedure's non-invasive nature and ability to spare critical vessels and bile ducts offer promising alternatives to traditional treatments.
A randomized clinical trial found that a voice-activated cognitive behavioral therapy program improved insomnia symptoms in breast cancer survivors. The intervention, delivered in an in-home setting, demonstrated efficacy in reducing sleep disturbances and enhancing overall quality of life.
Older cancer survivors are at a higher risk of stroke, heart attack, and hospital admission for heart failure. Chemotherapy is also linked to elevated rates of these conditions.
A new study found that patients with 4 or 5 identified risk factors, including age 18-24 years and schizophrenia spectrum disorders, had over 100 times the incidence of Neuroleptic Malignant Syndrome. The data provide a basis for early identification and monitoring of children and youth at elevated risk.
A recent study found a correlation between higher anti-PD-1 autoantibody levels and lower survival rates in patients with advanced liver cancer, suggesting these autoantibodies as potential biomarkers for predicting treatment response. The discovery aims to improve treatment regimens for patients with liver cancer.
New study finds that extended estrogen suppression using aromatase inhibitors for hormone receptor-positive postmenopausal breast cancer is safe and does not increase the risk of coronary artery calcification. The duration of treatment and presence of osteoporosis were not associated with increased coronary artery calcification scores.
The CABINET trial demonstrates that cabozantinib significantly improves median progression-free survival (PFS) for patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors. The treatment also shows promise across all clinical subgroups, including primary tumor site and grade.
Researchers at UCSF used cryogenic electron microscopy to study the protein TGF-Beta, which plays a crucial role in development and cancer. They found that TGF-Beta can signal even when bound to a 'straitjacket' within the cell membrane, challenging decades-old dogma on its function.
Two studies found breastfeeding after breast cancer diagnosis is safe and feasible for young patients with specific genetic variations, as well as hormone receptor-positive breast cancer survivors. A third study shows a telephone-based coaching program can significantly increase physical activity in overweight patients, potentially imp...
The Phase I/II trial of AZD8205, a topoisomerase 1 inhibitor ADC targeting B7-H4, demonstrated partial responses in ovarian, breast, and endometrial cancers. Notably, only two patients experienced severe toxicities, indicating a favorable safety profile.